Silencing of METTL14 decreases the m6A level in RNA transcripts and enhances cancer metastasis, both in vitro and in vivo [161], and downregulation of METTL14 in HCC serves as an adverse prognostic factor for recurrence-free survival. Here, METTL14 is linked to hepatocellular carcinoma.